Shenzhen Hepalink Pharmaceutical Group Co., Ltd.
SHEZF · OTC
6/30/2025 | 3/31/2025 | 12/31/2024 | 9/30/2024 | |
|---|---|---|---|---|
| Revenue | $1 | $1 | $1 | $1 |
| % Growth | 2.1% | 15.1% | -1.6% | – |
| Cost of Goods Sold | $1 | $1 | $1 | $1 |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | 34.9% | 27.3% | 33.4% | 29.5% |
| R&D Expenses | $0 | $0 | $0 | $0 |
| G&A Expenses | -$0 | $0 | -$0 | $0 |
| SG&A Expenses | $0 | $0 | -$0 | $0 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | -$0 | $1 | -$0 |
| Operating Expenses | $0 | $0 | $1 | $0 |
| Operating Income | $0 | $0 | -$0 | $0 |
| % Margin | 21.5% | 12.8% | -13.4% | 9.8% |
| Other Income/Exp. Net | $0 | -$0 | $0 | -$0 |
| Pre-Tax Income | $0 | $0 | -$0 | $0 |
| Tax Expense | $0 | $0 | -$0 | $0 |
| Net Income | $0 | $0 | -$0 | $0 |
| % Margin | 18.6% | 11.2% | -11% | 9.5% |
| EPS | 0.18 | 0.11 | -0.091 | 0.079 |
| % Growth | 63.6% | 221% | -214.5% | – |
| EPS Diluted | 0.18 | 0.11 | -0.091 | 0.079 |
| Weighted Avg Shares Out | 1 | 1 | 1 | 1 |
| Weighted Avg Shares Out Dil | 1 | 1 | 1 | 1 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $0 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $0 | $0 | $0 | $0 |
| EBITDA | $0 | $0 | -$0 | $0 |
| % Margin | 22.7% | 14.4% | -10.8% | 14.7% |